Performance status of real-world oncology patients before and after first course of chemotherapy

Journal of Community and Supportive Oncology

Volumn 12, Issue 5, 2014, Pages 163-170

  Paoli, Carly J ^a   Bach, Bruce A ^a   Quach, David ^b   Tsai, Kai Tai ^c   Wong, Bruce ^d   Kallich, Joel ^e  

^a AMGEN INC   (United States)

^b IQVIA   (United States)

^c Bruce Wong Consulting   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Big Health Data ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ENZALUTAMIDE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL PRACTICE; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PROSTATE CANCER; RETROSPECTIVE STUDY; SELF CARE;

EID: 84988517920     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0041     Document Type: Article

References (26)

1. Oken MM, Creech RH, Torney DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
2. Myers J, Gardiner K, Harris K, et al. Evaluating correlation and interrater reliability for four performance scales in the palliative care setting. J Pain Symptom Manage. 2010;39:250-258.
3. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patient and their oncologists agree? Brit J Cancer. 2003;89:1022-1027.
4. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A:1135-41.
5. Sørenson JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67:773-775.
6. Finkelstein DM, Cassileth BR, Bonomi PD, Ruckdeschel JC, Ezdinli EZ, Wolter JM. A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1988;11:630-633.
7. Jordhøy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S. Quality of life in advanced cancer patients: The impact of sociodemographic and medical characteristics. Br J Cancer. 2001;85:1478-1485.
8. Sengeløv L, Kamby C, Geertsen P, Andersen LJ, von der Maase H. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol. 2000;46:357-64.
9. Capewell S, Sudlow MF; for the Edinburgh Lung Cancer Group. Performance and prognosis in patients with lung cancer. Torax. 1990;45:951-956.
10. Tusquets I, Espinosa Arranz E, Méndez M, Gil JM, Guallar JL, Perulero N; PROSA Study investigators. Epidemiologic study to assess patient involvement in choice of adjuvant chemotherapy for breast cancer (PROSA Study). Clin Transl Oncol. 2009;11: 221-227.
11. Wedding U, Koch A, Röhrig B, et al. Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy. Acta Oncol. 2008;47:56-62.
12. Chen H, Cantor A, Meyer J, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 2003;97:1107-1114.
13. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102.
14. Albain KS, Crowley JJ, LeBlanc M; Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618-1626.
15. Wheler J, Tsimberidou AM, Moulder S, et al. Clinical outcomes of patients with breast cancer in a phase I clinic: The M.D. Anderson cancer center experience. Clin Breast Cancer. 2010;10:46-51.
16. Christodoulou C, Rizos M, Galani E, Rellos K, Skarlos DV, Michalopoulos A. Performance status (PS): A simple predictor of short-Term outcome of cancer patients with solid tumors admitted to the intensive care unit (ICU). Anticancer Res. 2007;27:2945-2948.
17. Mor V, Laliberte L, Morris JN, Wiemann M. Te Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53: 2002-2007.
18. Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemother-Apy (TOPICAL): A double-blind, placebo-controlled, phase III trial. Lancet Oncol. 2012;13: 1161-1170.
19. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
20. National Cancer Institute. Oxaliplatin, leucovorin, and fuorouracil with or without bevacizumab in treating patients who have undergone surgery for stage II colon cancer (NCT00217737). http://www. cancer.gov/clinicaltrials/search/view?cdrid=443410&version=Health Professional. Accessed June 26, 2013.
21. National Institutes of Health. Ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery (NCT01274338). http://clinicaltrials. gov/show/NCT01274338. Accessed June 26, 2013.
22. National Institutes of Health. Chemotherapy with or without bevacizumab in treating patients with stage IB, stage II, or stage IIIA non-small [cell] lung cancer that was removed by surgery (NCT00324805). http://clinicaltrials.gov/show/NCT00324805. Accessed June 26, 2013.
23. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Survival among non-small cell lung cancer patients with poor performance status after first-line chemotherapy. Lung Cancer. 2012;77:545-549.
24. Martinez-Salamanca JI, Shariat SF, Rodriguez JC, et al. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: An international study. BJU Int. 2012;109:1155-1161.
25. Penel N, Glabbeke MV, Mathoulin-Pelissier S, et al. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: The European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer. 2011;104:1544-1550.
26. Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol.2011;29:1151-1158.